Felix J. F. Herth

Jul 11, 2024 | erj.ersjournals.com | Justin Garner |Felix J. F. Herth

FootnotesConflicts of interest: J.L. Garner is a co-investigator on trials conducted by Apreo, CSA Medical, Galvanize and Pulmonx. P.L. Shah is an investigator on clinical trials conducted by Pulmonx, Nuvaria, CSA Medical, Creo Medical, Apreo, Galavanize Therapeutics, Intuitive and Huma, a consultant for Apreo, Ambu, Olympus, ERBE and Creo Medical, and has received lecture fees from Galavnize, Pulmonx and Phillips. F.

Jan 1, 2024 | openres.ersjournals.com | Judith Brock |Frank C. Sciurba |Gerard J. Criner |Felix J. F. Herth

IntroductionCOPD remains a major healthcare issue with a global impact, currently being the fourth leading cause of death worldwide [1]. The high impact of morbidity and mortality associated with COPD includes a significant economic burden, with COPD accounting for >50% of the direct costs of respiratory disease, and an impact on productivity at work and home.